
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.
-
NICE recommends step-change targeted treatment for people with early breast cancer
Around 4,000 people are set to benefit from a step-change in treatment for early breast cancer following today’s (17 June 2022) provisional approval by NICE of abemaciclib in combination with hormone therapy as an option after surgery.
-
New treatment to increase the chances of a successful kidney transplant recommended by NICE
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance today (16 June 2022).
-
Hundreds of thousands set to benefit as NICE final draft guidance recommends new treatment to prevent heart attacks and strokes in people with raised blood fats
NICE has today (10 June 2022) published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of a type of blood fat called triglycerides.